Callisto system now supports seven validated DNA library preparation workflows across multiple sequencing platforms and chemistries.
Volta Labs has expanded its Callisto Sample Preparation Platform to include fully automated DNA library preparation for whole genome sequencing across multiple sequencer platforms and chemistries.
The Boston-based company announced that Callisto now offers seven validated whole-genome sequencing DNA applications, supporting workflows for Illumina, Oxford Nanopore Technologies, PacBio, Element Biosciences, and Ultima Genomics platforms. The system accommodates chemistries from Illumina, New England Biolabs, Twist Bioscience, PacBio, Qiagen, and Watchmaker Genomics.
The expanded platform includes five short-read kits and two long-read kits across the five sequencer platforms, requiring no method scripting or protocol development. According to the company, the pre-validated methods can reduce hands-on time by up to 75% to 80% and cut time-to-data by 50% to 70%.
“Callisto was engineered to deliver flexibility and reproducibility at scale,” says Udayan Umapathi, CEO of Volta Labs, in a release. “By supporting multiple sequencing chemistries and platforms, we’ve eliminated workflow dependencies, allowing laboratories to achieve high-quality, automated whole genome sequencing on the systems that align best with their experimental and operational requirements.”
Performance and Validation Data
The platform achieves a cross-site coefficient of variation of 5% or less for key quality control metrics, according to Volta Labs. The pre-validated methods allow teams to move to production within weeks, potentially eliminating four to six months of method development and optimization.
The seven Callisto whole genome sequencing applications are currently available in North America and the European Union, with additional regions planned for rollout in the first quarter of 2026. The applications are in use at multiple ISO-certified laboratories and are designated for research use only.
Clinical Applications Showcase
Volta Labs present edthe platform’s capabilities at the Association for Molecular Pathology Annual Meeting on Nov 12, 2025. The workshop, titled “Reimagining NGS Prep: End-to-End Automation for Faster Clinical Insights,” featured Dr Lennart Kester from the Prinses Máxima Center for Pediatric Oncology discussing his team’s experience using Callisto to streamline whole-genome sequencing workflows in pediatric oncology.
The app-based system represents what the company describes as the industry’s largest portfolio of PCR-free whole-genome sequencing preparation workflows on a single platform. The system operates independently of sequencing platforms, reagent formulations, or vendor constraints.
Founded in 2018, Volta Labs focuses on genomic sample preparation automation for research and clinical environments. The company offers app bundles and promotional launch packages for the new whole-genome sequencing capabilities.
Photo caption: A user selects their app of choice for Callisto to run
Photo credit: Volta Labs
